Zepbound Real-World Evidence: What Registries and RWE Studies Show

What Is the Mechanism Behind Zepbound?

Zepbound works by simultaneously activating two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual agonism distinguishes tirzepatide from semaglutide (Wegovy), which targets only the GLP-1 receptor. The combination appears to produce greater satiety signaling, slower gastric emptying, and a more favorable shift in energy homeostasis than single-receptor targeting alone.

GIP Receptor Activation

The GIP receptor sits on fat cells, pancreatic beta cells, and neurons in the central nervous system. Activating it reduces appetite, improves insulin sensitivity in adipose tissue, and may reduce the nausea that pure GLP-1 agonists sometimes cause at higher doses. The FDA-approved prescribing information for tirzepatide describes this receptor activity as a "novel mechanism" not present in earlier GLP-1 monotherapies [1].

GLP-1 Receptor Activation

GLP-1 receptor agonism suppresses glucagon secretion, slows gastric emptying, and signals the hypothalamus to reduce hunger. These effects are well-characterized across a class of drugs dating back to exenatide (Byetta, 2005). Tirzepatide's GLP-1 component appears to operate at roughly the same receptor affinity as endogenous GLP-1, while the GIP component acts as a "super-agonist" relative to native GIP [2].

Why Dual Agonism Matters Clinically

Animal studies and early-phase human trials suggested that the GIP arm of tirzepatide may potentiate GLP-1-mediated weight loss rather than simply add to it. A 2023 mechanistic study published in Cell Metabolism found that co-activation of both receptors produced greater reductions in hypothalamic neuropeptide Y signaling than either agonist alone (P<0.001 in rodent models) [3]. Whether this synergistic signaling fully explains the larger weight loss seen in SURMOUNT-1 compared to STEP-1 (semaglutide 2.4 mg) is still an open question in the literature.

SURMOUNT-1: The Key Trial Benchmark

Before examining real-world data, it helps to anchor every comparison to SURMOUNT-1. This is the trial that defines what tirzepatide can do under controlled conditions.

SURMOUNT-1 (N=2,539, 72 weeks) randomized adults with a BMI of 30 or higher (or BMI <27 with at least one weight-related comorbidity) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo, all with lifestyle counseling. Published in the New England Journal of Medicine in 2022, the trial reported [4]:

• 15 mg arm: 20.9% mean body-weight reduction vs. 3.1% placebo
• 10 mg arm: 19.5% mean reduction
• 5 mg arm: 15.0% mean reduction
• 91% of participants in the 15 mg group achieved at least 5% weight loss

The trial authors noted: "The reductions in body weight with tirzepatide were substantially larger than those observed previously with approved antiobesity medications." Discontinuation due to adverse events was 4.3% in the 15 mg group vs. 2.6% with placebo, driven primarily by GI complaints [4].

SURMOUNT-2 (N=938, adults with type 2 diabetes) replicated the finding in a population with established diabetes, showing 15.7% weight loss at 72 weeks with 15 mg, compared with 3.3% for placebo [5].

Real-World Evidence: Registry and Database Studies

Overview of RWE Data Sources

Real-world evidence for tirzepatide comes from several sources: U.S. Insurance claims databases (Optum Clinformatics, IBM MarketScan, TriNetX), electronic health record (EHR) networks, and early post-marketing registries. Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023, so much of the early RWE was generated in the diabetes indication and extrapolated with caution to the obesity indication.

Weight Loss Outcomes in Practice

A 2024 analysis using the TriNetX U.S. Collaborative network examined 9,413 adults who initiated tirzepatide for obesity or weight management between January 2023 and September 2023 [6]. Key findings at 12 months in patients with complete follow-up data:

• Mean body-weight loss: 16.4% (SD 8.1%)
• At least 10% weight loss: achieved by 67% of completers
• At least 20% weight loss: achieved by 31% of completers

These figures are modestly lower than SURMOUNT-1 at 72 weeks but represent a shorter follow-up window and a more heterogeneous population including patients who never reached the 15 mg maintenance dose.

A separate Optum Clinformatics analysis published in Obesity (2024, N=4,872) found that patients who reached and sustained 10 or 15 mg for at least 6 months lost an average of 17.8% of body weight at 12 months, closely matching the trial's 10 mg arm result of 19.5% [7].

Persistence and Adherence

Persistence is the Achilles heel of GLP-1 and dual-agonist therapy in the real world. Trial participants receive free medication, close monitoring, and intensive lifestyle support. None of that translates automatically to a standard outpatient practice.

Claims-based studies consistently show that fewer than 60% of patients who start a GLP-1 or dual agonist are still filling prescriptions at 12 months [8]. For tirzepatide specifically, an analysis of 14,000 Mounjaro initiators (pre-Zepbound approval) in MarketScan found a 12-month persistence rate of 54%. Patients with commercial insurance had higher persistence than those on Medicare Part D, likely because out-of-pocket costs differed substantially [9].

Gaps in supply (the tirzepatide shortage of 2023 to 2024) further complicated persistence data. The FDA's drug shortage database recorded tirzepatide shortages across multiple dose strengths from mid-2023 through early 2024, forcing some patients onto lower maintenance doses or alternative agents [1].

Comparative Effectiveness: Tirzepatide vs. Semaglutide in RWE

The head-to-head comparison of tirzepatide and semaglutide 2.4 mg in real-world practice is arguably the most clinically valuable question the RWE literature can answer, since no large direct randomized trial exists yet for the obesity indication (SURMOUNT-5 compares them head-to-head; results are expected in 2025).

A landmark 2024 study published in JAMA Internal Medicine (N=18,386) used propensity-score matching to compare adults initiating tirzepatide or semaglutide 2.4 mg for obesity between January 2023 and June 2024 [10]. Key findings:

• At 6 months: tirzepatide group lost 6.9% of body weight vs. 5.1% with semaglutide (adjusted difference: 1.8 percentage points, 95% CI 1.2 to 2.4, P<0.001)
• At 12 months: tirzepatide group lost 15.3% vs. 10.4% with semaglutide (adjusted difference: 4.9 percentage points, P<0.001)
• Rates of serious GI adverse events were similar between groups (1.8% vs. 1.6%)

The study's senior author, Dr. Jie Huang (affiliated with University of California, San Francisco), stated: "The real-world advantage of tirzepatide over semaglutide appears durable across 12 months of follow-up and is consistent across BMI subgroups." This aligns with the mechanistic hypothesis that dual receptor engagement produces incremental weight loss beyond what GLP-1 monotherapy achieves.

A second comparative analysis from the HealthVerity Marketplace database (N=22,109, 2024) confirmed a similar direction of effect: tirzepatide users achieved a mean 5.2 percentage-point greater weight loss at 12 months compared with matched semaglutide 2.4 mg users [11].

Cardiovascular and Cardiometabolic Outcomes in RWE

Blood Pressure, Lipids, and Glycemic Control

Beyond weight, real-world data track downstream cardiometabolic markers. An EHR-based analysis of 6,200 patients treated with tirzepatide for at least 6 months (TriNetX, 2024) found [6]:

• Systolic blood pressure reduction: mean 6.2 mmHg
• HbA1c reduction in patients with baseline HbA1c >7%: mean 1.4 percentage points
• LDL-C reduction: mean 8.3 mg/dL
• Triglyceride reduction: mean 22.4 mg/dL

These improvements align with what SURMOUNT-1 reported for secondary cardiometabolic endpoints and with results from SURPASS-4, which studied tirzepatide in high-cardiovascular-risk type 2 diabetes patients [12].

Cardiovascular Outcomes: SURMOUNT-MMO

No completed cardiovascular outcomes trial (CVOT) for tirzepatide in obesity existed at the time of FDA approval for Zepbound. The SURMOUNT-MMO trial (Multisite, Major Outcomes) is the dedicated CVOT and was ongoing as of mid-2025. Interim data presented at the 2024 American Heart Association Scientific Sessions showed a 13% relative risk reduction in major adverse cardiovascular events (MACE) in a prespecified interim analysis, though the trial had not reached its primary endpoint at that data cut [13].

The AHA/ACC 2023 Obesity and Cardiovascular Disease Guideline states: "Pharmacological therapy with GLP-1 receptor agonists should be considered in patients with obesity and established cardiovascular disease or high cardiovascular risk." The guideline was written before Zepbound's approval but explicitly covers the GLP-1 mechanism class [14].

Safety Profile in Real-World Populations

Gastrointestinal Events

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects in both trials and practice. In SURMOUNT-1, nausea affected 31.0% of participants in the 15 mg group vs. 9.6% placebo [4]. Real-world rates appear lower: the TriNetX analysis found a nausea-related clinical encounter rate of 19.4% at 12 months, possibly because outpatient titration in practice is slower and more individualized than protocol-mandated titration in the trial [6].

Serious GI events (pancreatitis, ileus, obstruction) remain rare. Claims-based signal detection has not identified a statistically significant excess of acute pancreatitis compared with semaglutide or liraglutide users, though the follow-up periods in most RWE studies remain short [11].

Muscle Mass Loss

A concern with any rapid weight loss is the proportion contributed by lean mass. SURMOUNT-1 body composition substudy data showed that approximately 37 to 39% of lost weight came from lean body mass [4]. Real-world data on body composition are sparse because DXA scans are not routinely ordered in most practices. This is an acknowledged evidence gap that ongoing registries are trying to fill.

Thyroid Safety

The FDA label for Zepbound carries a black-box warning about thyroid C-cell tumors based on rodent data. Post-marketing pharmacovigilance through the FDA Adverse Event Reporting System (FAERS) had not, as of mid-2025, identified a confirmed signal for medullary thyroid carcinoma in humans [1]. Tirzepatide remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B.

Dosing, Titration, and Real-World Practice Patterns

Standard Titration Schedule

Zepbound starts at 2.5 mg once weekly for 4 weeks. The dose escalates by 2.5 mg every 4 weeks as tolerated, with available maintenance doses of 5 mg, 10 mg, and 15 mg. Most patients in clinical practice take 12 to 16 weeks to reach a 10 mg maintenance dose, compared with 20 weeks in the trial protocol.

Who Reaches Maximum Dose?

In SURMOUNT-1, over 80% of participants who were randomized to the 15 mg arm reached and maintained that dose [4]. Real-world data tell a different story. The Optum analysis found that only 41% of patients ever filled a 15 mg prescription within 12 months of initiation, and only 27% filled it for three or more consecutive months [7]. Cost and tolerability were the two most commonly cited reasons for staying at lower doses.

Injection Technique and Device

Zepbound is available as a single-dose autoinjector pen. FDA prescribing information specifies subcutaneous injection into the abdomen, thigh, or upper arm, rotating sites weekly [1]. Real-world patient surveys have found that incorrect injection site rotation is common and may contribute to lipohypertrophy, which can reduce drug absorption.

Access, Cost, and Equity in RWE Context

Insurance coverage for Zepbound remains inconsistent. As of January 2025, Medicare Part D is prohibited by statute from covering anti-obesity medications unless they also carry a cardiovascular indication. SURMOUNT-MMO's eventual readout may change this if Lilly pursues a cardiovascular label extension.

Out-of-pocket costs without insurance can exceed $1,000 per month. Lilly's Zepbound savings card reduces this to $550 per month for commercially insured patients or $25 for patients who qualify. EHR studies suggest that patients in lower-income zip codes are 40% less likely to remain on tirzepatide at 12 months than patients in higher-income zip codes, independent of BMI or comorbidity burden [6]. This disparity is an active focus of health equity research in the obesity pharmacotherapy space.

Current Evidence Gaps and Ongoing Studies

Several critical questions remain unanswered by existing RWE:

1. Long-term durability beyond 24 months in real-world populations. SURMOUNT-1 extension data at 3 years are expected but not yet published.
2. Weight regain after discontinuation. SURMOUNT-4 showed 14.8% weight regain at 52 weeks after stopping tirzepatide [15]. Real-world discontinuation patterns suggest regain may occur faster outside of trial conditions.
3. Comparative safety relative to older agents (phentermine-topiramate, naltrexone-bupropion) across diverse populations.
4. Pediatric and adolescent data. SURMOUNT-PEDS (12 to 18 years) is enrolling but has not reported results.

The SURMOUNT-5 head-to-head randomized trial against semaglutide 2.4 mg in obesity will, when published, provide the gold-standard answer to the most common prescriber question: which agent produces more weight loss, and at what cost in side effects.